 Lymphocytes, Tumor-Infiltrating
"Lymphocytes, Tumor-Infiltrating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
| Descriptor ID |
D016246
|
| MeSH Number(s) |
A11.118.637.555.567.650 A15.145.229.637.555.567.650 A15.382.490.555.567.650
|
| Concept/Terms |
Lymphocytes, Tumor-Infiltrating- Lymphocytes, Tumor-Infiltrating
- Lymphocytes, Tumor Infiltrating
- Tumor-Infiltrating Lymphocytes
- Lymphocyte, Tumor-Infiltrating
- Tumor Infiltrating Lymphocytes
- Tumor-Infiltrating Lymphocyte
Tumor-Derived Activated Cells- Tumor-Derived Activated Cells
- Activated Cell, Tumor-Derived
- Activated Cells, Tumor-Derived
- Tumor Derived Activated Cells
- Tumor-Derived Activated Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphocytes, Tumor-Infiltrating".
Below are MeSH descriptors whose meaning is more specific than "Lymphocytes, Tumor-Infiltrating".
This graph shows the total number of publications written about "Lymphocytes, Tumor-Infiltrating" by people in this website by year, and whether "Lymphocytes, Tumor-Infiltrating" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 2 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 0 | 3 | 3 | | 2013 | 3 | 1 | 4 | | 2014 | 4 | 4 | 8 | | 2015 | 5 | 2 | 7 | | 2016 | 9 | 5 | 14 | | 2017 | 4 | 4 | 8 | | 2018 | 9 | 5 | 14 | | 2019 | 7 | 9 | 16 | | 2020 | 5 | 7 | 12 | | 2021 | 5 | 10 | 15 | | 2022 | 3 | 8 | 11 | | 2023 | 1 | 7 | 8 | | 2024 | 5 | 3 | 8 | | 2025 | 8 | 5 | 13 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphocytes, Tumor-Infiltrating" by people in Profiles.
-
Hoyt-Miggelbrink AM, Waibl Polania J, Wachsmuth L, Lorrey S, Mohan A, Hardigan A, Blandford E, Lerner E, Wilkinson D, Hotchkiss KM, Cook S, Hemmers S, Patel A, Ayasoufi K, Fecci P. Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clin Cancer Res. 2026 Feb 17; 32(4):782-800.
-
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23; 15(1):37112.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19; 16(1):7717.
-
Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025 Dec; 14(1):2546402.
-
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.
-
Tagayasu Y, Yamada R, Kanemitsu K, Kondo Y, Fujiwara Y, Tanizaki T, Itoyama R, Kitano Y, Hayashi H, Komohara Y, Iwatsuki M. Increased Infiltration of Tissue-Resident Memory T Cells Predicts a Good Response to Anti-PD-L1 Immunotherapy in Extrahepatic Cholangiocarcinoma. Pathobiology. 2026; 93(1):1-11.
-
Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Nov 20; 43(33):3565-3572.
-
Agustoni F, Yu H, Ellison K, Smith D, Mitchell P, Rivalland G, Dziadziuszko R, Gao D, Ren S, Rivard CJ, San Millan I, Corallo S, Pedrazzoli P, Hirsch FR. Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts. Front Immunol. 2025; 16:1586782.
-
Goff SL, Rosenberg SA. Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI. J Immunother Cancer. 2025 Apr 09; 13(4).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|